Keigo Hayashi

Nov 1, 2024 | ard.bmj.com | Vanessa L Kronzer |Katrina A Williamson |Keigo Hayashi |Elizabeth Atkinson

Uncovering specific genetic-respiratory disease endotypes for rheumatoid arthritis risk Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Sep 11, 2024 | acrjournals.onlinelibrary.wiley.com | Suzanne Byrne |Gregory McDermott |Keigo Hayashi |Pierre-Antoine Juge

Supporting Information Filename Description acr25432-sup-0001-Disclosureform.pdfPDF document, 1 MB Disclosure form acr25432-sup-0002-Supinfo.docxWord 2007 document , 187.2 KB Appendix S1: Supporting Information. REFERENCES 1, , , et al. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology (Oxford) 2021; 60(8): 3689–3698. 2, , , et al.

May 9, 2024 | ard.bmj.com | Sara K. Tedeschi |Keigo Hayashi |Yuqing Zhang |Hyon K. Choi

Objective To investigate gout flare rates based on repeated serum urate (SU) measurements in a randomised controlled trial of urate-lowering therapy (ULT), accounting for dropout and death. Methods We performed a secondary analysis using data from Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout, which randomised participants to febuxostat or allopurinol, titrated to target SU <6 mg/dL with flare prophylaxis for 6 months.

May 8, 2024 | ard.bmj.com | Sara K. Tedeschi |Keigo Hayashi |Yuqing Zhang |Hyon K. Choi

AbstractObjective To investigate gout flare rates based on repeated serum urate (SU) measurements in a randomised controlled trial of urate-lowering therapy (ULT), accounting for dropout and death. Methods We performed a secondary analysis using data from Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout, which randomised participants to febuxostat or allopurinol, titrated to target SU <6 mg/dL with flare prophylaxis for 6 months.

Jan 15, 2024 | acrjournals.onlinelibrary.wiley.com | Sara K. Tedeschi |Keigo Hayashi |Ann K. Rosenthal |Muneet Gill

Objective Calcium pyrophosphate deposition (CPPD) disease was associated with osteopenia in two cross-sectional studies. We compared fracture risks in patients with acute calcium pyrophosphate (CPP) crystal arthritis versus matched comparators. Methods We performed a longitudinal cohort study using electronic health record data from a single large academic health system, with data from 1991 to 2023.